)
Biofrontera (BFRI) investor relations material
Biofrontera Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 revenue rose 29.8% YoY to $9.1M; growth included $1.6M of orders pulled forward ahead of ITC-related supply restrictions.
FDA approved Ameluz PDT for superficial basal cell carcinoma (sBCC), the first PDT approved in the U.S. for a cancerous skin tumor.
CBP ruled redesigned RhodoLED XL-C outside the ITC exclusion order, restoring U.S. import and sales access for the redesigned lamp.
Financial highlights
Q3 revenue was $9.1M vs. $7.0M YoY; 9M revenue was $31.2M vs. $24.6M, up 26.6%.
Q3 net loss narrowed to $6.4M from $6.6M; 9M net loss narrowed to $11.8M from $16.2M.
Q3 gross profit was $6.7M vs. $4.9M; cost of revenues was $2.3M vs. $2.0M.
Q3 SG&A was $12.5M vs. $10.4M, reflecting higher ITC legal fees, lamp manufacturing and regulatory costs, and sales commissions; R&D was $0.5M vs. $0.9M.
9M Adjusted EBITDA loss improved to $9.3M from $15.5M.
Outlook and guidance
Ameluz sBCC commercialization is planned from late Q4 2026 through Q1 2027; launch preparation and training are underway.
An sNDA to expand the actinic keratosis label to the extremities, neck, and trunk was submitted in October; the PDUFA date is August 5, 2027.
The 2026 minimum annual Ameluz order requirement of 80,000 tubes is on track.
Q4 gross margin is expected near 80%; Q4 is typically the strongest revenue quarter.
Remediation of affected lamps is expected to be substantially complete by the end of Q2 2027; management expects a clear sBCC reimbursement path at launch.
- Q2 2026 revenue up 32.9% with margin gains, but legal and capital risks remain.BFRI
Q2 2026 - All proposals, including director elections and plan amendments, were approved by shareholders.BFRI
AGM 2026 - Revenue and margins are rising as new indications and regulatory milestones drive future growth.BFRI
Lytham Partners Spring 2026 Investor Conference - Q1 2026 saw 17% revenue growth, 80% gross margin, and clinical and legal developments.BFRI
Q1 2026 - Stockholders will vote on director elections, incentive plan expansion, and auditor ratification.BFRI
Proxy filing - Healthcare innovators project strong growth through new indications, acquisitions, and market expansion.BFRI
2nd Annual Lytham Partners Healthcare Investor Summit - Record revenues, margin expansion, and Q4 profitability set the stage for 2026 growth.BFRI
Q4 2025 - Revenue up 9% to $8.6M, net loss narrowed, but liquidity and Nasdaq risks persist.BFRI
Q1 2025 - Record sales and clinical milestones set the stage for margin gains and growth in 2025.BFRI
Q4 2024
)
)
)
)
)
)
)
)